Logo

Genaissance, Bayer Partner in Search for Genomic Markers

Jan 21, 2003

NEW YORK, Jan. 21 - Genaissance Pharmaceuticals and Bayer Diagnostics said today they are collaborating on finding pharmacogenomics markers for drug safety and efficacy.

 

In the partnership, Genaissance will use its HAP technology to analyze clinical samples provided by the diagnostics division of Bayer HealthCare.

 

Terms of the deal call for Genaissance to receive royalties and rights to perform diagnostic tests developed and marketed by Bayer, according to the companies.

 

Financial details of the agreement were not disclosed.

 

Click here for more information.

 

 

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.